Search

Your search keyword '"Bruix"' showing total 4,902 results

Search Constraints

Start Over You searched for: Author "Bruix" Remove constraint Author: "Bruix"
4,902 results on '"Bruix"'

Search Results

156. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

162. The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis

163. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

165. Insights into insulin resistance and calcification in the Myocardium in type 2 dDiabetes: a coronary artery analysis

166. A Pooled Multicentric Analysis of Survival in 580 Patients

170. Methods of Quantification

172. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

174. 770 Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors

178. 770 Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors

186. “Very Early” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?

188. International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis

189. Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT

190. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

191. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

194. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events

195. Liver Imaging Reporting and Data System: Review of Pros and Cons

196. Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

197. Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs

198. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot

200. Contributors

Catalog

Books, media, physical & digital resources